{"disease":{"id":"anemia-due-to-bleeding-uterine-leiomyoma","name":"Anemia due to Bleeding Uterine Leiomyoma","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":4,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"leuprorelin","indication_name":"Anemia due to Bleeding Uterine Leiomyoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lupron","generic_name":"leuprorelin","company_name":"Accord Healthcare S.L.U.","drug_phase":"marketed","molecular_target":"GnRH receptors","drug_class":"Gonadotropin Releasing Hormone Receptor Agonist","quality_score":65,"revenue":null,"mechanism":"Leuprolide acetate, a long-acting GnRH analog, initially stimulates then suppresses pituitary gonadotropins, reducing gonadal steroid secretion."},{"drug_id":"leuprolide","indication_name":"Anemia due to Bleeding Uterine Leiomyoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lupron","generic_name":"leuprolide","company_name":"Accord Healthcare S.L.U.","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptor","drug_class":"Gonadotropin Releasing Hormone Receptor Agonist","quality_score":75,"revenue":null,"mechanism":"Lupron works by binding to and activating the gonadotropin-releasing hormone receptor, which ultimately leads to a decrease in the production of sex hormones."},{"drug_id":"leuprolide-acetate","indication_name":"Anemia due to Bleeding Uterine Leiomyoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Leuprolide Acetate","generic_name":"leuprolide-acetate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptor","drug_class":"leuprorelin","quality_score":10,"revenue":null,"mechanism":"Leuprolide acetate is a manufactured version of a hormone that regulates growth and development, used to treat hormone-related conditions."},{"drug_id":"eligard","indication_name":"Anemia due to Bleeding Uterine Leiomyoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Eligard","company_name":"Astellas Pharma Europe Ltd.","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptor, Gonadotropin-releasing hormone receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[{"drug_id":"leuprorelin","guideline_body":"FDA label","recommendation":"LUPRON DEPOT 3.75 mg, used concomitantly with iron therapy, is indicated for the preoperative hematologic improvement of women with anemia caused by fibroids for whom three months of hormonal suppression is deemed necessary.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null}],"source":"Drug Landscape verified database"}